Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
By Sriparna Roy March 18 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for psoriasis, the company said on Wednesday, paving the way for a more convenient ...
The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...
The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced.
"Walking around with this very visible, very robust ailment has a pretty tremendous impact on your mental health," Maddox ...
Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could ...
This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic ...
Johnson & Johnson (JNJ) stock is in focus as US approves its once-daily pill Icotyde developed with Protagonist Therapeutics ...
Portia has not taken Sotyktu. Portia Brown* has long been drawn toward helping people cope with challenges. Since volunteering as a college student to work with her peers to educate them about sexual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results